Form 4: Denali Therapeutics Director Jennifer E. Cook Reports Acquisition of Shares and Stock Options

Director Jennifer E. Cook reported acquiring shares and stock options in Denali Therapeutics Inc. on May 31, 2024.

Summary

• On May 31, 2024, Jennifer E. Cook, a director of Denali Therapeutics Inc., reported acquiring 5,967 shares of common stock represented by Restricted Stock Units (RSUs) and a contingent right to receive one share of common stock at a price of $0.
• Cook also acquired 17,901 stock options with an exercise price of $18.56, exercisable starting May 31, 2024, and expiring on May 31, 2034.
• Following these transactions, Cook beneficially owns 21,496 shares of common stock, including 5,967 unvested RSUs, and 17,901 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction report. The acquisition of shares and options can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Insider transactions are routinely monitored across the biotechnology industry, with companies like Biogen, Amgen, and Gilead Sciences also subject to similar reporting requirements.
• The vesting schedules for RSUs and stock options are typical, often tied to employment tenure or company performance, aligning with industry norms.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding insider activity.
• The acquisition of shares and options by a director can be perceived positively by investors.

Key Dates